{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:25:58Z","timestamp":1764019558490,"version":"3.32.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T00:00:00Z","timestamp":1156464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Acute hepatitis C virus (HCV) infection evolves to chronicity in 50\u201384% cases. Treatment with interferon\u2010<jats:italic>\u03b1<\/jats:italic>(IFN\u2010<jats:italic>\u03b1<\/jats:italic>) was repeatedly found to provide sustained cure rates higher than that in chronic HCV infection, but the optimal treatment strategy has not yet been defined. In a multicentre open\u2010label study, we investigated the therapeutic performance of a short course of pegylated (peg) IFN\u2010<jats:italic>\u03b1<\/jats:italic>in patients with acute HCV hepatitis. Peg IFN\u2010<jats:italic>\u03b1<\/jats:italic>2b, 1.0\u20131.5\u2003<jats:italic>\u03bc<\/jats:italic>g\/kg weekly, was administered for 12\u2003weeks. Forty\u2010six patients were enrolled; 26 of them were intravenous drug users. Eleven patients had jaundice. Treatment was started within 1\u201390\u2003days from the peak alanine aminotransferase. Treatment was well tolerated with a single dropout (2%). Thirty\u2010three of 46 patients (72%) had a sustained virological response (SVR) after a 6\u2003months post\u2010treatment follow\u2010up, 8 (17%) relapsed after treatment and 4 were nonresponders (9%). A lower peak viraemia, receiving at least 1.2\u2003<jats:italic>\u03bc<\/jats:italic>g\/kg of peg IFN\u2010<jats:italic>\u03b1<\/jats:italic>, and a negative HCV\u2010RNA at week 4 and week 12 were predictors of SVR. Thus, in patients with early (week 4) viral response, a short course of peg IFN\u2010<jats:italic>\u03b1<\/jats:italic>at a weekly dose &gt;1.2\u2003<jats:italic>\u03bc<\/jats:italic>g\/kg, may be a valuable option for the treatment of acute HCV hepatitis.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2006.00802.x","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T19:44:29Z","timestamp":1156535069000},"page":"116-121","source":"Crossref","is-referenced-by-count":52,"title":["A short course of pegylated interferon\u2010<i>\u03b1<\/i>in acute HCV hepatitis"],"prefix":"10.1111","volume":"14","author":[{"given":"G.","family":"Calleri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gaiottino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. G.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Bargiacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Audagnotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"De Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Caramello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,12,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22112"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis B","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.12.012"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011232"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20266"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21043"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20196"},{"key":"e_1_2_8_11_2","first-page":"294","article-title":"Early treatment of acute hepatitis C with interferon alpha\u20102b or interferon alfa\u20102b plus ribavirin: study of sixteen patients","volume":"27","author":"Rocca P","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00007-0"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042608"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20467"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200102000-00010"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.018"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290311"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00461-6"},{"key":"e_1_2_8_20_2","first-page":"181","article-title":"Natural beta interferon in acute type\u2010C hepatitis patients: a randomized controlled trial","volume":"30","author":"Calleri G","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2006.00802.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2006.00802.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T16:07:57Z","timestamp":1736525277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2006.00802.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,21]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1365-2893.2006.00802.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2006.00802.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2006,12,21]]}}}